Abstract
Introduction: Numerous clinical trials are currently investigating the potential of nitric
oxide (NO) as an antiviral agent against coronaviruses, including SARS-CoV-2. Additionally,
some researchers have reported positive effects of certain Sartans against SARS-CoV-2.
Method: Considering the impact of NO-Sartans on the cardiovascular system, we have compiled
information on the general structure, synthesis methods, and biological studies of synthesized NOSartans.
In silico evaluation of all NO-Sartans and approved sartans against three key SARS-CoV-
-2 targets, namely Mpro (PDB ID: 6LU7), NSP16 (PDB ID: 6WKQ), and ACE-2 (PDB ID: 1R4L),
was performed using MOE.
Results: Almost all NO-Sartans and approved sartans demonstrated promising results in inhibiting
these SARS-CoV-2 targets. Compound 36 (CLC-1280) showed the best docking scores against
the three evaluated targets and was further evaluated using molecular dynamics (MD) simulations.
Conclusion: Based on our in silico studies, CLC-1280 (a Valsartan dinitrate) has the potential to
be considered as an inhibitor of the SARS-CoV-2 virus. However, further in vitro and in vivo evaluations
are necessary for the drug development process.
Graphical Abstract
[7]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell 2020; 181(2): 271-80.
[9]
Yan L, Ge J, Zheng L, Zhang Y, Gao Y, Wang T. Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis. Cell 2021; 184(1): 184-93.
[14]
Shefa U, Yeo SG, Kim M-S, Song IO. Role of gasotransmitters in oxidative stresses, neuroinflammation, and neuronal repair. BioMed Research International 2017; 2017
[26]
Xi-zhi JG, Thomas PG, Eds. New fronts emerge in the influenza cytokine storm Seminars in immunopathology. Springer 2017.
[29]
Wolak T, Kalaora R, Hatan M, Yarkoni S, Greenberg D, Bortey E, et al. Inhaled nitric oxide for the treatment of COVID-19 and other viral pneumonias in adults. TP92 TP092 clinical advances IN SARS-COV-2 and COVID-19: American Thoracic Society 2021; 3849.
[30]
Razzaghi M, Kamani E. Role low-power blue laser with a wavelength of 405 nm in increasing the level of nitric oxide in increasing the resistance of cells to the virus (COVID-19) and its effect on virus (COVID-19) mortality in vitro. OSP Journal of Case Reports 2020; 2(3): 1-2.
[36]
Tejvir S, McKaya G. Potential role of Nitric Oxide (NO) and Silver/Silver Nanoparticles in the treatment of COVID-19 Infections. Int J Mol Sci 2023; 24(24): 17162.
[40]
Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. The potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2. in vivo 2020; 34(3): 1567-88.
[51]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Bin Cao Clinical features of patients infected with. 2019; 497-506.
[111]
Kow CS, Hasan SS. The potential benefit of telmisartan to protect overweight COPD patients from the acquisition of COVID-19. Obesity 2020.
[114]
Mostafa MA. Role of Zidovudine and Candesartan in the Novel SARS-CoV-2 Treatment Trials; Theoretical Study. AIJR Preprints 2020.
[184]
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature 2020; 579: 270-3.
[193]
Turner P. XMGRACE, Version 51 19 Center for Coastal and Land-Margin Research. Beaverton, OR: Oregon Graduate Institute of Science and Technology 2005.